氯氮平血浆浓度与治疗反应关联的系统综述、荟萃分析及个体数据荟萃分析
荟萃分析显示应答者氯氮平血浆浓度平均比非应答者高117 ng/mL,超过各研究阈值的患者应答可能性更高(OR=2.94,p<0.001)。个体数据荟萃分析确定治疗反应阈值为407 ng/mL,敏感度71%、特异度89.1%。
要点
- 氯氮平血浆浓度与临床反应相关,应答者平均浓度高117 ng/mL。
- 血浆浓度超过阈值的患者应答可能性更高(OR=2.94,p<0.001)。
- 治疗反应阈值为407 ng/mL,敏感度71%、特异度89.1%。
核心结论
- 氯氮平血浆浓度与良好临床反应相关,应答者与非应答者平均差异为117 ng/mL。
- 确定治疗反应阈值为407 ng/mL,具有较高的判别能力,敏感度和特异度分别为71%和89.1%。
研究设计与样本
- 采用汇总数据研究临床结局改善与氯氮平、去甲氯氮平浓度及浓度变异系数的关联,并利用个体数据评估浓度与BPRS评分变化的关系。
主要发现
- 应答者氯氮平血浆浓度平均比非应答者高117 ng/mL。
- 血浆氯氮平浓度高于各研究确定阈值的患者应答可能性更高(OR=2.94,p<0.001)。
- 去甲氯氮平血浆浓度与临床反应无关。
- 个体数据荟萃分析支持氯氮平浓度与BPRS评分变化和/或临床反应概率的关联。
- 氯氮平血浆浓度个体间波动越大与临床反应丧失相关。
关键数值与推荐
- 治疗反应阈值为407 ng/mL,敏感度71%、特异度89.1%。
- 应答者与非应答者氯氮平血浆浓度平均差异为117 ng/mL。
- 浓度高于阈值的患者应答OR=2.94(p<0.001)。
临床怎么用
- 临床可依据氯氮平血浆浓度而非仅剂量来优化治疗药物监测。
- 可参考407 ng/mL作为治疗反应阈值评估患者应答可能性。
- 关注氯氮平血浆浓度的个体内波动,波动增大可能提示临床反应丧失。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVES: Although therapeutic drug monitoring of clozapine is recommended, its optimisation is often adjusted only on the basis of dosage. The aim of this study was to assess the link between clozapine plasma concentrations and clinical response by a meta-analysis of published studies and by an individual participant data meta-analysis. METHODS: We conducted a computerised search of bibliographic databases (EMBASE, PubMed, Clinical Trials, and Web of Science) to identify studies that assessed the relationship between clozapine serum or plasma concentrations and clinical efficacy. Using pooled data, we investigated the association between improvement of clinical outcome and clozapine or norclozapine plasma concentrations, the sum of clozapine and norclozapine plasma concentrations, and the coefficient of variation of clozapine plasma concentrations. Using available individual data, we assessed the relationship between clozapine plasma concentrations and clinical response (changes in the Brief Psychiatric Rating Scale score) and identified a threshold level for a favourable clinical response. RESULTS: Fifteen studies satisfied inclusion criteria. Our meta-analysis showed that responders had clozapine plasma concentrations that were, on average, 117 ng/mL higher than non-responders. The patients with plasma clozapine concentrations above the thresholds identified in each study had a higher likelihood of responding (odds ratio = 2.94, p < 0.001). Norclozapine plasma concentrations were not associated with a clinical response. The meta-analysis of individual data supported this result and confirmed the link between clozapine concentrations and a change in the Brief Psychiatric Rating Scale score and/or the probability of clinical response. Finally, with the analysis of the coefficient of variation of clozapine plasma concentrations, we found that a greater inter-individual fluctuation in plasma concentrations was associated with a loss of clinical response. CONCLUSIONS: Our work confirmed that, in contrast to clozapine doses, clozapine plasma concentrations were related to a favourable clinical response, with a mean difference between responders and non-responders of 117 ng/mL. A threshold for a treatment response of 407 ng/mL was determined, with a high discriminatory capacity, and a sensitivity and specificity of 71% and 89.1%, respectively.
引用
- Tralongo F, Konecki C, Feliu C, et al. Association Between Clozapine Plasma Concentrations and Treatment Response: A Systematic Review, Meta-analysis and Individual Participant Data Meta-analysis. Clin Pharmacokinet. 2023. PMID: 37145296. doi:10.1007/s40262-023-01247-1
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。